Takeda Pharmaceutical : Sustainability Activities Receive Multiple Accolades by Rigorous ESG Evaluators

Takeda is selected in other benchmark ESG indices as below:

Name of Index/Investment Universe*/Ratings	Company/ Organization Conducting Assessment	Country	Honors Awarded
Global 100 Most Sustainable Corporations in the World Index	Corporate Knights	CND	4th consecutive year
Dow Jones Sustainability Asia Pacific Index	S&P Dow Jones Indices	US	9th consecutive year
FTSE4Good Developed Index	FTSE Russel	UK	14th consecutive year
Ethibel EXCELLENCE Investment Register	Forum Ethibel	BEL	From July 2017

As a pharmaceutical company dedicated to improving people's lives, Takeda remains committed to fulfilling its social responsibilities in response to global needs.

About Takeda's Sustainable Value Report
Takeda's annual Sustainable Value Report showcases how the company is addressing the world's biggest challenges to sustainable development over the long-term. Data included are primarily non-financial, focusing on Takeda's diverse CSR commitments, as well as how CSR priorities are inextricably linked to the company's DNA. Takeda leverages such benchmarks as the international integrated reporting framework of the International Integrated Reporting Council (IIRC), United Nations Global Compact's advanced level assessment criteria, and Global Reporting Initiative (GRI) Standards to create a comprehensive report that incorporates high standards of transparency and disclosure, targeting a broad range of stakeholders.
For more information, visit
https://www.takeda.com/corporate-responsibility/Sustainable-Value-Report/

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience, and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com

Media Contacts:
Japanese Media
Kazumi Kobayashi
[e-mail] [phone]

Media outside Japan
Tsuyoshi Tada
[e-mail]
[phone]